Metabolomics Laboratory, College of Pharmacy, Korea University, Sejong City 30019, Republic of Korea.
Department of Control and Instrumentation on Engineering, Korea University, Sejong City 30019, Republic of Korea.
Int J Mol Med. 2018 Feb;41(2):1069-1077. doi: 10.3892/ijmm.2017.3275. Epub 2017 Nov 21.
Type 2 diabetes mellitus (DM) is a progressive disease and the rate of progression from non-diabetes to DM varies considerably between individuals, ranging from a few months to many years. It is important to understand the mechanisms underlying the progression of diabetes. In the present study, a high-resolution metabolomics (HRM) analysis was performed to detect potential biomarkers and pathways regulating the mode of onset by comparing subjects who developed and did not develop type 2 DM at the second year in a 3-year prospective cohort study. Metabolic profiles correlated with progression to DM were examined. The subjects (n=98) were classified into four groups: Control (did not develop DM for 3 years), DM (diagnosed with DM at the start of the study), DM onset at the third year and DM onset at the second year. The focus was on the comparison of serum samples of the DM groups with onset at the second and third year from the first year, where these two groups had not developed DM, yet. Analyses involved sample examination using liquid chromatography-mass spectrometry-based HRM and multivariate statistical analysis of the data. Metabolic differences were identified across all analyses with the affected pathways involved in metabolism associated with steroid biosynthesis and bile acid biosynthesis. In the first year, higher levels of cholesterol {mass-to charge ratio (m/z) 369.35, (M+H-H2O)+}, 25-hydroxycholesterol [m/z 403.36, (M+H)+], 3α,7α-dihydroxy-5β-cholestane [m/z 443.33, (M+K)+], 4α-methylzymosterol-4-carboxylate [m/z 425.34, (M+H‑H2O)+], and lower levels of 24,25-dihydrolanosterol [m/z 429.40, (M+H)+] were evident in the group with DM onset at the second year compared with those in the group with DM onset at the third year. These results, with a focus on the cholesterol biosynthesis pathway, point to important aspects in the development of DM and may aid in the development of more effective means of treatment and prevention.
2 型糖尿病(DM)是一种进行性疾病,从非糖尿病到糖尿病的进展速度在个体之间差异很大,从数月到数年不等。了解糖尿病进展的机制非常重要。在本研究中,通过比较在 3 年前瞻性队列研究中第二年发生和未发生 2 型糖尿病的受试者,进行高分辨率代谢组学(HRM)分析,以检测潜在的生物标志物和调节发病模式的途径。检查了与进展为糖尿病相关的代谢谱。将受试者(n=98)分为四组:对照组(3 年内未发生糖尿病)、糖尿病组(研究开始时被诊断为糖尿病)、第三年发生糖尿病组和第二年发生糖尿病组。重点是比较第二年和第三年发生糖尿病组与第一年未发生糖尿病组的血清样本,这两组在第一年都没有发生糖尿病。分析包括使用基于液相色谱-质谱的 HRM 对样本进行检查,以及对数据进行多变量统计分析。所有分析都确定了代谢差异,受影响的途径涉及与类固醇生物合成和胆汁酸生物合成相关的代谢。在第一年,与第二年发生糖尿病组相比,第三年发生糖尿病组中胆固醇[质荷比(m/z)369.35,(M+H-H2O)+]、25-羟基胆固醇[m/z 403.36,(M+H)+]、3α,7α-二羟基-5β-胆甾烷[m/z 443.33,(M+K)+]、4α-甲基孕甾醇-4-羧酸酯[m/z 425.34,(M+H-H2O)+]的水平较高,24,25-二氢羊毛甾醇[m/z 429.40,(M+H)+]的水平较低。这些结果侧重于胆固醇生物合成途径,指出了糖尿病发展的重要方面,可能有助于开发更有效的治疗和预防方法。